chlorpromazine has been researched along with Alzheimer Disease in 36 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14." | 1.48 | Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018) |
| " The long-term administration of neuroleptics in severe cases of SDAT caused a significant increase of SLI (p < 0." | 1.30 | Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type. ( Cramer, H; Hamann, G; Reuner, C; Schimrigk, K; Strittmatter, M; Strubel, D, 1997) |
| "Patients with Down syndrome are at high risk for early Alzheimer's disease." | 1.29 | Dementia and Down syndrome. ( Shank, JC; Tyler, CV, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (11.11) | 18.7374 |
| 1990's | 4 (11.11) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 19 (52.78) | 24.3611 |
| 2020's | 5 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 3 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 2 |
| Rodríguez-Franco, MI | 5 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 1 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 1 |
| Badia, A | 1 |
| Clos, MV | 1 |
| Mancini, F | 1 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 3 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 2 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 2 |
| Liang, H | 2 |
| Wang, ZY | 1 |
| Sun, Y | 3 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 6 |
| Li, X | 6 |
| Luo, Z | 1 |
| Sheng, J | 1 |
| Lu, C | 1 |
| Yan, J | 1 |
| Liu, A | 1 |
| Luo, HB | 1 |
| Miao, H | 1 |
| Meng, F | 1 |
| Rochais, C | 1 |
| Lecoutey, C | 1 |
| Gaven, F | 1 |
| Giannoni, P | 1 |
| Hamidouche, K | 1 |
| Hedou, D | 1 |
| Dubost, E | 1 |
| Genest, D | 1 |
| Yahiaoui, S | 1 |
| Freret, T | 1 |
| Bouet, V | 1 |
| Dauphin, F | 1 |
| Sopkova de Oliveira Santos, J | 1 |
| Ballandonne, C | 1 |
| Corvaisier, S | 1 |
| Malzert-Fréon, A | 1 |
| Legay, R | 1 |
| Boulouard, M | 1 |
| Claeysen, S | 1 |
| Dallemagne, P | 1 |
| Xie, SS | 3 |
| Wang, X | 1 |
| Jiang, N | 2 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Lan, JS | 1 |
| Li, ZR | 1 |
| Kong, LY | 1 |
| Wang, Z | 2 |
| Wang, Y | 4 |
| Wang, B | 1 |
| Li, W | 1 |
| Hroch, L | 1 |
| Benek, O | 1 |
| Guest, P | 1 |
| Aitken, L | 1 |
| Soukup, O | 3 |
| Janockova, J | 1 |
| Musil, K | 1 |
| Dohnal, V | 1 |
| Dolezal, R | 2 |
| Kuca, K | 2 |
| Smith, TK | 1 |
| Gunn-Moore, F | 1 |
| Musilek, K | 1 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Monjas, L | 1 |
| Gil, C | 1 |
| De Simone, A | 1 |
| Baschieri, A | 1 |
| Apperley, KYP | 1 |
| Chen, HH | 1 |
| Guardigni, M | 1 |
| Montanari, S | 1 |
| Kobrlova, T | 1 |
| Valgimigli, L | 1 |
| Keillor, JW | 1 |
| Basso, M | 1 |
| Milelli, A | 1 |
| Hu, J | 2 |
| Yang, X | 1 |
| Feng, X | 1 |
| Chan, ASC | 1 |
| Kumar, D | 1 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 1 |
| Gutti, G | 1 |
| Krishnamurthy, S | 1 |
| Modi, G | 1 |
| Singh, SK | 1 |
| Hepnarova, V | 1 |
| Korabecny, J | 1 |
| Matouskova, L | 1 |
| Jost, P | 1 |
| Muckova, L | 1 |
| Hrabinova, M | 1 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Nepovimova, E | 1 |
| Spilovska, K | 1 |
| Mezeiova, E | 1 |
| Pham, NL | 1 |
| Jun, D | 1 |
| Staud, F | 1 |
| Kaping, D | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Srivastava, P | 1 |
| Tripathi, PN | 1 |
| Sharma, P | 1 |
| Shrivastava, SK | 1 |
| Liu, J | 2 |
| Tang, C | 1 |
| Pang, C | 1 |
| Li, Q | 2 |
| Qin, Y | 1 |
| Nong, X | 1 |
| Zhang, Z | 2 |
| Guo, J | 2 |
| Cheng, M | 2 |
| Tang, W | 1 |
| Liang, N | 1 |
| Jiang, X | 2 |
| Zhou, J | 1 |
| Chen, L | 1 |
| Duan, Y | 1 |
| Huang, J | 1 |
| Liu, C | 2 |
| Chen, Y | 2 |
| Liu, W | 2 |
| Sun, H | 3 |
| Feng, F | 2 |
| Qu, W | 1 |
| Xing, C | 1 |
| Lyu, W | 1 |
| Wang, S | 1 |
| Chen, T | 1 |
| Zhou, W | 1 |
| Wan, Y | 1 |
| Wang, R | 1 |
| Fang, Y | 1 |
| Jin, Y | 1 |
| Xi, M | 1 |
| Feng, C | 1 |
| Du, K | 1 |
| Lv, W | 1 |
| Du, C | 1 |
| Shen, R | 1 |
| UMANSKAIA, RM | 1 |
| PERSSON, I | 1 |
| Aziz, AA | 1 |
| Leeming, RJ | 1 |
| Blair, JA | 1 |
| Auchus, AP | 1 |
| Freeman, A | 1 |
| Green, RC | 1 |
| Tyler, CV | 1 |
| Shank, JC | 1 |
| Strittmatter, M | 1 |
| Cramer, H | 1 |
| Reuner, C | 1 |
| Strubel, D | 1 |
| Hamann, G | 1 |
| Schimrigk, K | 1 |
| Devanand, DP | 1 |
| Hatch, CD | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Asnes, DP | 1 |
36 other studies available for chlorpromazine and Alzheimer Disease
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Azoles; Butyrylcholinestera | 2013 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
Topics: Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Computer Simulation; Cryst | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; | 2015 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cel | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; G | 2017 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres | 2019 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose | 2020 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2021 |
Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzothiazoles; Benzylamines; Biphen | 2021 |
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholineste | 2022 |
[On the results of aminazin therapy of patients with presenile psychoses].
Topics: Alzheimer Disease; Chlorpromazine; Depressive Disorder, Major; Mental Disorders; Psychotic Disorders | 1960 |
[Chlorpromazine in therapy of arteriosclerotic psychosis and senile dementia].
Topics: Alzheimer Disease; Arteriosclerosis; Chlorpromazine; Dementia; Mental Disorders; Psychotic Disorders | 1955 |
Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type.
Topics: Aged; Alzheimer Disease; Biopterins; Chlorpromazine; Female; Humans; Male; Neurotransmitter Agents; | 1983 |
Agitated behavior relieved following treatment of cervical dystonia in dementia.
Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Ag | 1995 |
Dementia and Down syndrome.
Topics: Adult; Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Disease Progression; Down Syndrome; | 1996 |
Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Chromatography, High Pressure Liquid; | 1997 |
Antipsychotic treatment in outpatients with dementia.
Topics: Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Dementia; Dose-Respo | 1996 |
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy | 2001 |
Psychopharmacology in the aged. Use of major psychotropic medications in treatment of the elderly: case examples.
Topics: Adjustment Disorders; Aged; Alzheimer Disease; Amitriptyline; Benztropine; Bipolar Disorder; Cataton | 1974 |